Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proliferation of qui tam suits?

This article was originally published in The Gray Sheet

Executive Summary

The Department of Justice currently has over 100 qui tam cases in its docket alleging fraud and abuse by medical device firms, OIG Chief Counsel Lewis Morris said at the recent Pharma, Biotech and Device Colloquium in Princeton, N.J. He predicted that "in the next year or two, as [DoJ] starts to roll out some of these device cases, sales people will start reflecting perhaps on the bogus research and compensation arrangements they have struck with certain doctors...to lock in purchases of certain devices. Once the genie is out of the bottle and they start reporting these instant millionaires, the device industry is going to see more and more qui tams." DoJ issued a subpoena to five major orthopedic device manufacturers in April requesting certain contracts and remuneration agreements between the firms and physicians using their products (1"The Gray Sheet" April 4, 2005, p. 3)...

You may also be interested in...



DoJ Probe Into Orthopedic Industry Could Rattle Upward Pricing Trend

Several subpoenas of orthopedic manufacturers by the U.S. attorney's office in Newark, N.J. appear to be aimed at alleviating pricing pressure on hospitals for orthopedic devices

WHO No-Go Not A Swan Song For Remdesivir In India?

The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things. 

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel